1.Effects of psoralen on the proliferation, invasion and migration of HTB-47 and CRL-1932 renal cancer cell lines and related mechanisms
Lingxing YUAN ; Xiufeng LI ; Chuanlan GU ; Shijun LU ; Qingyan LOU ; Yuan LIU ; Fanlu LIN ; Yingmin XU
International Journal of Biomedical Engineering 2021;44(1):34-38
Objective:To study the effect of psoralen on the proliferation, invasion and migration of HTB-47 and CRL-1932 renal cancer cells cultured in vitro, and to further explore the internal mechanism of psoralen inhibiting renal cancer.Methods:The experimental group was HTB-47 and CRL-1932 renal cancer cells treated with dimethyl sulfoxide solution containing 30 μg/ml psoralen, and the control group was renal cancer cells treated with dimethyl sulfoxide. Scratch test, CCK8, Transwell, and Western blot were used to detect the effect of psoralen on renal cancer cells.Results:Compared with the control group, the proliferation, invasion and migration of renal cancer cells treated with psoralen in the experimental group were significantly inhibited. In the renal cancer cells treated with psoralen, the protein expression levels of MKI67, PCNA, MMP2 and MMP9 were significantly decreased (all P<0.05). Conclusions:Psoralen can significantly inhibit the proliferation, invasion and migration of HTB-47 and CRL-1932 renal cancer cells in vitro. The mechanism may be to inhibit the progression of renal cancer by regulating MKI67, PCNA, MMP2 and MMP9.
2.Molecular Mechanism and Progression of Primary Resistance to EGFR-TKI - Analysis of 2 Cases.
Meirong LIU ; Fanlu MENG ; Qing MA ; Liyan GU ; Diansheng ZHONG
Chinese Journal of Lung Cancer 2019;22(1):52-56
Tyrosine kinase inhibitor (TKI) have been proved to be effective in the treatment of advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) sensitive mutation, which is superior to chemotherapy. However, there are still some patients with sensitive mutations have primary drug resistance. It may be related to the coexistence of susceptible and resistant mutations of EGFR gene, downstream mutations of EGFR pathway, MET amplification and BIM deletion polymorphism. We present 2 cases of primary drug resistance and analyze the reasons.
.
Carcinoma, Non-Small-Cell Lung
;
diagnostic imaging
;
drug therapy
;
genetics
;
Disease Progression
;
Drug Resistance, Neoplasm
;
drug effects
;
genetics
;
ErbB Receptors
;
antagonists & inhibitors
;
genetics
;
Fatal Outcome
;
Humans
;
Lung Neoplasms
;
diagnostic imaging
;
drug therapy
;
genetics
;
Male
;
Middle Aged
;
Mutation
;
Protein Kinase Inhibitors
;
therapeutic use
;
Treatment Outcome
3.Severe Adverse Reactions Induced by the Chest Injection of Elemene: An Analysis of 7 Cases.
Fei GAO ; Yi SHAO ; Diansheng ZHONG ; Xia LIU ; Fanlu MENG
Chinese Journal of Lung Cancer 2018;21(6):458-462
BACKGROUND:
Malignant pleural effusion (MPE) refers to pleural effusion which arises from primary malignant tumor of pleura or other pleural metastatic tumors. Injection of elemene in chest makes good effect on the treatment of MPE, and is widely used in clinic. Adverse effects also exist, but the severe adverse effects and relevant managements are rarely reported. The aim of this study is to observe the adverse reactions induced by the treatment of malignant pleural effusion through elemene injection and to explore the solutions.
METHODS:
A retrospective analysis was made on 14 cases of patients receiving intra-pleural injections with elemene, and the incidence of severe adverse reactions of 7 cases were disscussed in detail.
RESULTS:
Most of the severe adverse reactions caused by elemene were severe chest pain, dyspnea, wheezing, clouding of consciousness and coagulopathy.
CONCLUSIONS
Strict screening, full preprocessing and close monitoring are necessary to prevent serious adverse reactions caused by elemene injection in the treatment of malignant pleural effusion.
Aged
;
Female
;
Humans
;
Injections
;
Male
;
Middle Aged
;
Pleural Effusion, Malignant
;
drug therapy
;
Retrospective Studies
;
Sesquiterpenes
;
administration & dosage
;
adverse effects
;
therapeutic use
;
Thorax
4.A Systematic Evaluation Study of a Mouse Model of Psoriasis with Pattern of Spleen Deficiency and Dampness Obstruction
Fanlu LIU ; Haojie SU ; Panyu ZHOU ; Yating ZHANG ; Qing WANG ; Yue SUN ; Hongyu YUE ; Jingjing WU ; Jianan WEI ; Ling HAN
Traditional Chinese Drug Research & Clinical Pharmacology 2024;35(10):1470-1482
Objective To construct a mouse model of psoriasis with spleen deficiency and dampness obstruction pattern and evaluate the model from multiple dimensions and directions,expects to provide research support for the study of traditional Chinese medicine (TCM) treatment of psoriasis with spleen deficiency and dampness obstruction pattern. Methods A mouse model of spleen deficiency and dampness obstruction pattern was established by feeding a high-fat diet,a mouse model of psoriasis vulgaris was established by externally applying imiquimod ointment,and a mouse model of psoriasis with spleen deficiency and dampness obstruction pattern was constructed by combining the above two models. Indications of spleen deficiency and dampness obstruction pattern were evaluated by comparing the body mass,food intake and water intake of mice in each group. The severity of psoriasis in mice was evaluated by comparing the area of skin lesions,PASI score,the value of transdermal water loss (TEWL),and histopathological morphological changes of skin under HE staining in each group. Flow cytometry was used to detect the expression in various cell types to evaluate the degree of inflammatory response of psoriasis in mice. Observation of adiposity index,changes in the histopathological morphology of liver tissue under HE staining,changes in the mRNA expression levels of related factors in liver tissue and adipose tissue of epididymis of mice detected by RT-qPCR,and changes of ABCA1 protein expression level of skin detected by Western Blot were used to evaluate the lipid metabolism disorders in mice. Results Compared with the mice in the psoriasis vulgaris model group,the mice in the model of psoriasis with pattern of spleen deficiency and dampness obstruction had significantly higher body mass (P<0.001),significantly lower food intake (P<0.005),and the symptoms of pattern of spleen deficiency and dampness obstruction such as greasy fur,mental fatigue,etc. appeared. The TWEL were significantly increased(P<0.001),and the PASI scores also significantly increased(P<0.001). HE results were found psoriasis-like manifestations including hypertrophy of the spinous layer and clubbed hyperplasia. The expression of CD11bhighLy6G+neutrophil subpopulation,CD11binLy6Chigh monocyte subpopulation,CD11binCD11chigh classical dendritic cell subpopulation,F4/80-CD11c+dendritic cell subpopulation was significantly increased (P<0.001). HE staining suggested that the cellular morphology of liver showed obvious vacuolated degeneration,and the index of subcutaneous white adiposity and epididymal adiposity index were both significantly increased (P<0.005). The mRNA levels of FABP4 and CD36 in liver tissue were significantly elevated(P<0.005,P<0.001),while the mRNA expression levels of ABCA1 and PPARγ in epididymal fat tissue were decreased (P<0.05,P<0.01). ABCA1 protein level in skin increased(P>0.05). Conclusion The mouse model of psoriasis with spleen deficiency and dampness obstruction pattern can be used as a reliable animal model for combining disease and pattern,which can provide a reference for further exploration of TCM in the treatment of psoriasis with spleen deficiency and dampness obstruction pattern.
5.Curative Effect of Aprepitant Preventing CINV.
Shasha GUAN ; Lisha ZHANG ; Diansheng ZHONG ; Qing MA ; Fanlu MENG ; Yi SHAO ; Tao YU ; Xia LIU
Chinese Journal of Lung Cancer 2018;21(10):800-804
BACKGROUND:
Chemotherapy is the most important method for cancer treatment. However, chemotherapy induced nausea and vomiting (CINV) has a profound effect on patients. In recent years, there have been new antiemetic drugs, such as aprepitant. We review the curative effect of aprepitant with tropisetron and dexamethasone for prevention of nausea and vomiting in patients receiving Cisplatin chemotherapy.
METHODS:
Observation is divided into three stages. Whole study phase (0-120 h after chemotherapy administration), acute phases (0-24 h), and delayed phase (24 h-120 h). The primary endpoints were complete response (CR) and complete prevention (CP) during the three different study phase.
RESULTS:
In the whole study phase, 86.02% of patients achieved CR; in acute phases and delayed phases were 89.25%, 87.1%, respectively. CP were 46.22%, 83.87%, 45.16%, respectively. Anti-CINV effect was significantly associated with age distribution (P=0.008).
CONCLUSIONS
Aprepitant with tropisetron and dexamethasone prevented effectively CNIV for patients receiving Cisplatin chemotherapy. This combination could improve the quality of life and the compliance of patient with chemotherapy.
Adult
;
Aged
;
Aged, 80 and over
;
Antineoplastic Agents
;
adverse effects
;
Aprepitant
;
Cisplatin
;
adverse effects
;
Female
;
Humans
;
Male
;
Middle Aged
;
Morpholines
;
pharmacology
;
Nausea
;
chemically induced
;
prevention & control
;
Quality of Life
;
Vomiting
;
chemically induced
;
prevention & control